{
  "name": "Cariprazine",
  "genericName": "cariprazine",
  "brandNames": ["Vraylar"],
  "tags": ["Antipsychotic", "Atypical Antipsychotic"],
  "dosing": {
    "adult_acute": "Schizophrenia: 1.5 mg once daily; Bipolar mania: 1.5 mg once daily; Bipolar depression: 1.5 mg once daily",
    "adult_maintenance": "Schizophrenia: 1.5-6 mg/day; Bipolar: 3-6 mg/day",
    "notes": "Very long half-life (1-3 weeks); effects persist weeks after discontinuation; partial agonist at D2/D3; FDA-approved for bipolar depression",
    "canadian_clinical": {
      "starting_dose": "1.5 mg once daily",
      "titration_schedule": "Increase by 1.5 mg increments; wait â‰¥2 weeks between adjustments due to long half-life",
      "max_dose_evidence": "6 mg/day",
      "max_dose_practice": "6 mg/day",
      "inpatient_strategy": "Start 1.5-3 mg daily; slow titration due to long half-life; effect may take 2-4 weeks",
      "outpatient_strategy": "Start 1.5 mg daily; increase every 2+ weeks; excellent for bipolar depression or negative symptoms"
    }
  },
  "warnings": [
    "Black box warning: Increased mortality in elderly with dementia-related psychosis",
    "VERY long half-life (1-3 weeks with active metabolites) - clinical effects persist weeks after stopping",
    "Akathisia common (15-20%) - most common reason for discontinuation",
    "EPS risk moderate",
    "Weight gain and metabolic effects (moderate, less than olanzapine/quetiapine)",
    "Approved for bipolar depression (alternative to quetiapine/lurasidone)",
    "May help negative symptoms of schizophrenia (D3 partial agonism)"
  ],
  "cautions": {
    "renal": "No adjustment for mild-moderate; not recommended if CrCl <30",
    "hepatic": "Not recommended in severe hepatic impairment",
    "pregnancy": "Pregnancy Category C; limited data"
  },
  "citations": ["Vraylar FDA Label", "APA Guidelines", "CANMAT Bipolar Guidelines"]
}
